Otlertuzumab (TRU‐016) is a humanized monoclonal antibody that targets CD37[1] designed for the treatment of cancer.[2]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | CD37 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C4660H7136N1246O1452S30 |
| Molar mass | 104809.42 g·mol−1 |
This drug was developed by Emergent BioSolutions and has been in clinical trials for lymphoma and Chronic Lymphocytic Leukemia (CLL)[3]
References
edit- ^ Payandeh Z, Noori E, Khalesi B, Mard-Soltani M, Abdolalizadeh J, Khalili S (December 2018). "Anti-CD37 targeted immunotherapy of B-Cell malignancies". Biotechnology Letters. 40 (11–12): 1459–1466. doi:10.1007/s10529-018-2612-6. PMID 30293139. S2CID 52925605.
- ^ "Otlertuzumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- ^ "Otlertuzumab". ClinicalTrails.gov. U.S. National Library of Medicine.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |